Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001214659-25-002917·Lakefront Biotherapeutics NV
Schedule 13D ownership disclosure
LAKEFRONT BIOTHERAPEUTICS NV
Ordinary Shares, no par value · CUSIP: 36315X101
Event date: 2025-02-07
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TANG CAPITAL MANAGEMENT, LLCReported CIK 0001232621
Shares: 4,910,525.00 · Class: 7.5%
- KEVIN TANGReported CIK 0001178579
Shares: 4,910,525.00 · Class: 7.5%
- TANG CAPITAL PARTNERS, LPReported CIK 0001191935
Shares: 2,723,147.00 · Class: 4.2%
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
Shares: 1,962,418.00 · Class: 3.0%
- TANG CAPITAL PARTNERS III, INC
Shares: 224,960.00 · Class: 0.3%
- TANG CAPITAL PARTNERS IV, INC
Shares: 0.00 · Class: 0%
- CONCENTRA BIOSCIENCES, LLCReported CIK 0001970065
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-25-002917
- Form type
- SCHEDULE 13D
- Filer
- Lakefront Biotherapeutics NV
- CIK
- CIK 1421876
- Filed
- Feb 14, 2025
- Reporting period
- Feb 07, 2025
- Description
- Schedule 13D beneficial ownership